PREDICTIVE ABILITY OF AVAILABLE 10 YEARS CARDIO-VASCULAR RISK ALGORITHMS IN SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE STUDY ON 2 ITALIAN LUPUS COHORT

D.P.E. Margiotta1, S. Fasano2, L. Navarini1, L. Pierro1, A. Riccardi2, G. Dolcini1, G. Valen
tini1, A. Aletra1. 1Unit of Immuno-Rheumatology, Universita Campus Bio-Medico di Roma, Rome, 2Rheumatology Unit, Universit degli studi della Campania Luigi Vanvitelli, Naples, Italy

Background: Patients with Systemic Lupus Erythematosus (SLE) present an increased incidence of Cardio-Vascular Events (CVE) compared to general population, and the difference with healthy subjects is particularly evident in young SLE women.

Objectives: The aim of this study is to assess the predictive ability of established 10 years CV risk models in SLE

Methods: A retrospective analysis of two Italian SLE prospective cohorts was performed. SLE patients without previous CVE, with age >25 years, a minimum continuous follow-up of 10 years and sufficient data to calculate the 10 years risk scores were enrolled. The 10 years CVE risk scores were calculated at the first observation and all CVE were prospectively recorded in the following 10 years.

We calculated the following scores: the QRisk3, the Framingham CV disease 10 years score, the HeartScore (Europe Low Risk) and the SLE CV Risk Score proposed by Petri et al. Discriminatory ability for CVE prediction was estimated by the area under the receiver operating characteristic curve. Hosmer-Lemeshow (HL) tests was used to evaluate calibration comparing the observed versus expected number of events.

Results: Analysis was performed on 131 SLE patients (mean baseline age of 37 ±11 years). We observed 10 CVE during the 10 years follow-up from baseline (3 acute coronary syndrome, 4 stroke, 1 transitory ischaemic attack and 2 peripheral artery disease). The AUC values were 0.75 (95% CI 0.55–0.94) for QRisk3, 0.66 (0.45–0.88) for Framingham score, 0.62 (0.41–0.82) for the HeartScore and 0.7 (95% CI 0.55–0.85) for the SLE CV risk score. The p-values of HL test were 0.8 for QRisk3 and SLE CV score and 0.4 for Framingham score and HeartScore, suggesting a good model fit for all the CV risk scores. Considering scores with better discriminative ability and calibration, 20% of CVE were observed with QRisk3 score lower than 3.6% and with SLE CV risk score between 6% and 8%. Discriminatory ability and calibration were improved by multiplying by 2 the Framingham score and the HeartScore.

Conclusions: The available CV risk scores demonstrate a moderate predictive ability of 10 years CVE in SLE. We observed a better model fit for QRisk3 and SLE CV risk score. Nevertheless, a considerable proportion of patients, with very low predicted CV risk, developed CVE during follow-up.

REFERENCES:

ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS IS CONSISTENTLY ASSOCIATED WITH INCREASED MORTALITY: A META-ANALYSIS

E-R. Hammond1, I.B. Marin2, M. Lin2, H. Nab2, H. Kan2, O. Onasanya2, J. C. Tierce2, X. Wang2, B. Deval2, G. C. Alexander2. 1AstraZeneca, Gaithersburg, MD; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 3AstraZeneca, Cambridge, UK

Background: More than half of all patients with systemic lupus erythematosus (SLE) develop organ damage over time, including damage to the kidney, skin, cardiovascular, musculoskeletal and central nervous systems. Several mechanisms have been associated with organ damage, including long-term steroid use. SLE organ damage, like comorbid disease, may contribute to increased mortality.

Objectives: We conducted a systematic literature review and meta-analysis of the association between organ damage in SLE and mortality.

Methods: A literature search (January 2000–February 2017) of PubMed, EMBASE, Cochrane Library, and Latin American and Caribbean Health Sciences Literature from four continents evaluating organ damage by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) and mortality was conducted. Exclusion criteria included non–English language articles and study designs that did not report original, population-level measures of association. We used a random-effects meta-analysis to evaluate studies that modelled SDI as a continuous predictor of mortality and reported hazard ratios (HR) associated with a 1-unit SDI increase.

Results: The search yielded 10 420 articles, of which, 21 prospective cohort studies were selected. Ten studies evaluating SDI as a continuous variable and reporting Hazard Ratios were pooled and meta-analysed. The pooled HR of mortality for a 1-unit increase in SDI was 1.34 (95% confidence interval [CI]: 1.21–1.44; p<0.001). A study of 213 patients followed for 13 years in China yielded the greatest risk of mortality for a 1-unit SDI increase (HR 3.65, [95% CI: 1.52–8.76]). When excluded from the meta-analysis, the pooled HR for mortality for a 1-unit increase in SDI was 1.32 (95% CI: 1.25–1.42; p<0.001). Four studies that evaluated SDI as binary variable reported HR for various SDI reference groups: SDI=0: HR 5.10 (95% CI: 1.99–13.03); SDI=1: HR 3.8 (95% CI: 1.30–16.40); SDI=3: HR 4.74 (95% CI: 1.55–14.51); and SDI=5: HR 55.12 (95% CI: 19.15–16.83). Two studies reported odds ratios (OR) as the measure of association; for a 1-unit SDI increase, the OR was 19.7 (95% CI: 5.30–72.50), and for SDI=0 as reference group, the OR was 12 (95% CI: 6.00–22.00).

Conclusions: Organ damage in SLE is consistently associated with increased mortality across studies from various countries, regardless of how it is modelled. Novel therapies that are potentially disease modifying and steroid sparing could reduce organ damage, improve overall outcomes, and decrease mortality in patients with SLE.

Disclosure of Interest: E. Hammond Employee of: AstraZeneca, I. Murini: None declared, D. Lin: None declared, H. Nab Employee of: AstraZeneca, H. Kan Shareholder of: GlaxoSmithKline, O. Onasanya: None declared, J. Tierce: None declared, X. Wang Employee of: AstraZeneca, B. Deval Employee of: AstraZeneca, G. C. Alexander Consultant for: Chair of the FDA’s Peripheral and Central Nervous System Advisory Committee, serves as a paid consultant to IQVIA, serves on the Advisory Board of MesoRx Innovations, and serves as a paid member of National Institutes of Health’s National Heart and Lung Advisory Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies. 


VALIDATION OF A DISEASE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE MEASURE FOR RUSSIAN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: LUPUSQOL-RUSSIAN

E. Aseeva1, L. Vorobyova1, S. Soloviev1, G. Kolibaeva2, S. Glukhova1, 1Intensive care department, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; 2Rheumatology department, National Center of Cardiology and Internal Medicine named after Academician M. Mirmahimov, Bishkek, Kyrgyzstan

Background: Improvements in the survival of patients with systemic lupus erythematosus (SLE) in Russia have to some extent paralleled that seen worldwide over the last 20 years, but have at times come at the cost of increased morbidity and reduction in health-related quality of life (HRQoL). Recently, a specific questionnaire to evaluate HRQoL in adult SLE patients (LupusQol) has been developed and validated in United Kingdom and in several European countries.

Objectives: To assess the validity of a LupusQol-Russian in adult SLE patients.

Methods: The LupusQol-Russian was administered to a cohort of Russian patients affected with SLE. To perform a control, QoL was evaluated also with SF-36. The Russian version of LupusQol questionnaire was developed by the University of Central Lancashire and the East Lancashire Hospitals NHS Trust (www.lupusqol.com), after a linguistic validation process. Disease activity was evaluated by the SLEDAI-2K, and chronic damage by the Systemic Lupus International

Disclosure of Interest: None declared.

Collaborating Clinics Damage Index score (SDI). Internal consistency and test-retest reliability, convergent and discriminant validity were examined.

Results: 328 Russian SLE patients were enrolled in the study (MF 30:298, mean age 34.4±11.5 years, mean disease duration 106.9±97.9 months; mean SLEDAI-2K 9.6±8.0, mean SII 0.2±0.6). The LupusQoL-Russian demonstrated substantial evidence of construct validity. Each domain showed good correlation when compared with equivalent domains of the SF-36 (p<0.001 for all comparisons), LupusQoL-Rus-

**Syndrome Disease Damage Index. Bivariate logistic regression models and multi-vari-ate analysis were used to establish the independent effect of patient character-

istics associated with pulmonary manifestations. The results were considered significant when the P value was less than 0.05.

**Results:** The SJOGREN-SER registry included 437 patients (95% women, median age at inclusion 59 years [50–68] and mean of ESSDAI 2 (IQ=0–

4). One hundred and seventeen patients (26.8%) had pulmonary manifestations (19.2% airway disease and 9.8% pulmonary involvement). Ten patients pre-sented both. Sociodemographic characteristics were: mean age 59.5 years (SD: 11.46), 94.9% women and 19.6% smokers or former smokers. Patients with pul-

monary manifestations had higher ESSDAI score (6 (SD 6) vs 4 (SD 5)), pro-

longed disease duration (10.05 years (SD: 7.15) vs 7.7 (SD 6.3)) and were ANA positive more frequently (94.9% vs 62.2%). Airway involvement preceded or occurred at the time of diagnosis in 46.4% of patients. Pulmonary involvement occurred 5 years after the diagnosis of pSS in 37.2% of them. (RS1) Twenty-nine patients (6.8%) were diagnosed with ILD. The most frequent radiological patterns were: Non-Specific Interstitial Pneumonia n=14, Usual Interstitial Pneumonia n=5, Lymphoctic Interstitial Pneumonia n=5 and Cryptogenic Organised Pneumonia n=2. Stepwise multivariate analysis was performed including the following variables: sex, age, laboratory findings, disease duration, smoking and ESSDAI. Disease duration, activity of pSS according to ESSDAI score and ANA positivity were factors associated with the development of pulmonary manifestations.

**Disclosure of Interest:** None declared

DOI: 10.1136/annrheumdis-2018-eular.3151

---

**CONCLUSIONS:** The LupusQoL-Russian is valid to assess quality of life in SLE patients.